Posted by Michael Wonder on 10 Nov 2022
Decision to fund long-acting paliperidone for people with schizophrenia and ibrutinib for people with chronic lymphocytic leukaemia
10 November 2022 - PHARMAC is pleased to announce a decision to fund two new medicines.
The medicines are:
- Paliperidone palmitate three-monthly depot injection (Invega Trinza) for patients with schizophrenia
- Ibrutinib (Imbruvica) for patients with relapsed or refractory chronic lymphocytic leukaemia, following treatment with venetoclax
